Business

Monoclonal Antibody Generating Service
Collaborative Research

Monoclonal Antibody Generating Service Collaborative Research

iBody provides an antibody generating service to companies’ R&D departments and academia, which need highly specific monoclonal antibodies that are difficult to obtain using conventional technologies. We also work on antibody mining together with clients as collaborative research for projects outside the scope of our packaging services.

 

Discovery and Development of Novel Antibody Therapeutics

Discovery and Development of Novel Antibody Therapeutics

iBody focuses on cancer, autoimmune diseases, and infectious diseases, where human antibodies play an important role in disease progression and suppression. We are also working on the discovery and development of new antibody therapeutics.
Using “Ecobody” technology, it is possible to obtain natural human antibodies that bind to human antigens in their in vivo form. Taking advantage of “Ecobody,” iBody can discover and develop therapeutics with excellent efficacy for diseases for which existing antibody-related drugs cannot elicit sufficient efficacy.

Business Model

Monoclonal Antibody Generating Service
Collaborative research

logo:iBody
arrow
academia

Mine monoclonal antibodies for customer’s needs

Drug discovery and licensing

ibody hospital
arrow
academia

Discover and develop novel antibody therapeutics and license for pharmaceutical companies

※The logos are published with permission from the respective companies and academic institutions.